Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PML Antibodies:
anti-Mouse (Murine) PML Antibodies:
anti-Rat (Rattus) PML Antibodies:
Go to our pre-filtered search.
Human Polyclonal PML Primary Antibody for ICC, IF - ABIN252967
Wimmer, Schreiner, Everett, Sirma, Groitl, Dobner: SUMO modification of E1B-55K oncoprotein regulates isoform-specific binding to the tumour suppressor protein PML. in Oncogene 2010
Show all 21 Pubmed References
Human Polyclonal PML Primary Antibody for ICC, IF - ABIN4346484
Campagna, Herranz, Garcia, Marcos-Villar, González-Santamaría, Gallego, Gutierrez, Collado, Serrano, Esteban, Rivas: SIRT1 stabilizes PML promoting its sumoylation. in Cell death and differentiation 2010
Show all 3 Pubmed References
Human Polyclonal PML Primary Antibody for ELISA, WB - ABIN1583526
Kolegraff, Nava, Helms, Parkos, Nusrat: Loss of desmocollin-2 confers a tumorigenic phenotype to colonic epithelial cells through activation of Akt/?-catenin signaling. in Molecular biology of the cell 2011
Show all 2 Pubmed References
Human Polyclonal PML Primary Antibody for ICC, IF - ABIN252968
Kuroki, Ariumi, Ikeda, Dansako, Wakita, Kato: Arsenic trioxide inhibits hepatitis C virus RNA replication through modulation of the glutathione redox system and oxidative stress. in Journal of virology 2009
Show all 2 Pubmed References
Mouse (Murine) Monoclonal PML Primary Antibody for ICC, IF - ABIN2668256
Evdokimov, Sharma, Lockett, Lualdi, Kuehn: Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3. in Journal of cell science 2008
Mechanically, mutant NPM1 (show NPM1 Antibodies) interacted with PML and mediated its delocalization as well as stabilization contributing to elevated autophagic activity and leukemic cell survival in vitro.
study revealed molecular mechanism of responsiveness of the PML-RARA (show RARA Antibodies) mutations to AS2O3 treatment; mutation S214L disrupted PML-arsenic binding, nuclear body formation, basal SUMOylation and degradation; mutation A216T showed moderate defect in AS2O3 response;, mutants L217F and S220G behave similarly to wild-type; findings suggest distinct mutants of PML-RARA (show RARA Antibodies) confer varying degree of AS2O3 resistance
Silencing of PML-RAR (show PRAM1 Antibodies) and RARalpha2 results in similar increases in the constitutive expression of several granulocytic differentiation markers.
Our findings unveil a novel essential oncogenic activity of PML/RARA (show RARA Antibodies) in Acute promyelocitic leukemia
Findings reveal a previously unrecognized role of c-Myc (show MYC Antibodies) as a potential ceRNA for PML/RARalpha (show RARA Antibodies) in acute promyelocytic leukemia.
PML loss promotes tumor development, providing a growth advantage to tumor cells that use autophagy as a cell survival strategy during stress conditions.
WDR4 (show WDR4 Antibodies) is an oncoprotein that negatively regulates PML via ubiquitination to promote lung cancer progression by fostering an immunosuppressive and prometastatic tumor microenvironment
Sumoylation of PML with SUMO2 (show SUMO2 Antibodies) by UBC9/UBE2I (show UBE2I Antibodies) can lead to formation of polymeric SUMO chains. Data suggest that coordination of growing poly-SUMO chain with "back side" binding site on UBC9/UBE2I (show UBE2I Antibodies) appears to be required for SUMO chain elongation on PML. (PML = promyelocytic leukemia protein; SUMO2 (show SUMO2 Antibodies) = small ubiquitin-like modifier 2 (show SUMO2 Antibodies); UBC9/UBE2I (show UBE2I Antibodies) = ubiquitin-conjugating enzyme (show Ube2t Antibodies) UBC9/UBE2I (show UBE2I Antibodies))
Data show that the cytoplasmic localization of promyelocytic leukaemia (PML) is mediated by its nuclear export in a chromosomal maintenance 1 (CRM1 (show XPO1 Antibodies))-dependent manner.
this study, we first observed that PML-positive intranuclear aggregates also appeared in controls and were not specific for the Neuronal Intranuclear Hyaline Inclusion Disease cases.
Promyelocytic leukemia protein Pml -/- cells showed a higher proliferation rate, compared to Pml +/+ cells.
PML protein organizes heterochromatin domains where it regulates histone H3.3 (show H3F3A Antibodies) deposition by ATRX (show ATRX Antibodies) and DAXX (show DAXX Antibodies).
Data indicate that promyelocytic leukemia protein knockout (Pml-/-) animals fail to properly activate oxidative stress-responsive p53 (show TP53 Antibodies) targets, whereas the NRF2 (show NFE2L2 Antibodies) response is amplified and accelerated.
data support a model in which activation of myogenic differentiation results in PML NB loss, chromatin reorganization and DAXX (show DAXX Antibodies) relocalization, and provides a paradigm for understanding the consequence of PML loss in other cellular contexts, such as during cancer development and progression
a regulatory role of ZNF451 (show ZNF451 Antibodies)-1 in fine-tuning physiological PML levels
The data demonstrate a dual role of PML in protection and recovery after brain injury.
This study designates PML protein and PML-NBs (show NLRP2 Antibodies) to be major cellular components involved in the control of Herpes simplex virus 1 (HSV-1) latency, probably during the entire life of an individual.
Study found that Promyelocytic leukemia protein (PML) is broadly expressed across the gray matter, with the highest levels in the cerebral and cerebellar cortices. PML bodies are broadly involved in activity-dependent nuclear phenomena in adult neurons
These findings suggest that the UBC9/PML/RNF4 axis plays a critical role as an important SUMO pathway in cardiac fibrosis. Modulating the protein levels of the pathway provides an attractive therapeutic target for the treatment of cardiac fibrosis and heart failure.
The protein encoded by this gene is a member of the tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. This phosphoprotein localizes to nuclear bodies where it functions as a transcription factor and tumor suppressor. Its expression is cell-cycle related and it regulates the p53 response to oncogenic signals. The gene is often involved in the translocation with the retinoic acid receptor alpha gene associated with acute promyelocytic leukemia (APL). Extensive alternative splicing of this gene results in several variations of the protein's central and C-terminal regions\; all variants encode the same N-terminus. Alternatively spliced transcript variants encoding different isoforms have been identified.
RING finger protein 71
, probable transcription factor PML
, promyelocytic leukemia protein
, promyelocytic leukemia, inducer of
, protein PML
, tripartite motif protein TRIM19
, tripartite motif-containing protein 19
, promyelocytic leukemia
, probable transcription factor PML-like